Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Window of Opportunity for Durvalumab (MEDI4736) Plus Metformin Trial of in Squamous Cell Carcinoma of the Head and Neck

NCT03618654 is registered in ClinicalTrials.gov with Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University as lead sponsor.

NCT NCT03618654
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03618654 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Window of Opportunity for Durvalumab (MEDI4736) Plus Metformin Trial of in Squamous Cell Carcinoma of the Head and Neck
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University
Phase
Phase 1
Overall status
Completed
Start date
November 1, 2018
Completion date
December 7, 2022
Enrollment
38 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

head and neck squamous cell carcinoma, oral cavity squamous cell carcinoma, oropharyngeal squamous cell carcinoma